Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kurzyna, M.
Right arrow Articles by Torbicki, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kurzyna, M.
Right arrow Articles by Torbicki, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Neurohormonal modulation in right ventricular failure

Marcin Kurzyna and Adam Torbicki*

Department of Chest Medicine, Institute of Tuberculosis and Lung Diseases, Ul Plocka 26, 01-138 Warszawa, Poland

* Corresponding author. Tel: +48 22 4312114; fax: +48 22 4312414. E-mail address: a.torbicki{at}igichp.edu.pl

Sympathetic system stimulation, followed by activation of the renin, angiotensin, and aldosterone system, is an important contributor to the vicious circle of chronic heart failure (CHF). Accounting for this excessive neurohormonal response resulted in major and highly effective changes in therapeutic approach to CHF, primarily due to left ventricular (LV) dysfunction. Indeed, this disturbed neurohormonal balance can be at least partly restored by adrenergic beta-receptor blockers, angiotensin-conversion inhibitors and receptor blockers, and aldosterone antagonists, with beneficial functional and prognostic effects. Right ventricular (RV) dysfunction due to severe pulmonary hypertension (PH) ultimately results in similar changes in systemic haemodynamics, which trigger neurohormonal response in LV failure, including low cardiac index and hypotension. However, the evidence related to the presence and clinical significance of neurohormonal activation in primarily RV failure is very limited. Are similar neurohormonal mechanisms contributing to vicious circle of RV failure induced by PH? Could experience gained from left heart failure treatment be useful to protect RV? This somewhat provocative article will review the existing evidence, current recommendations, and future directions related to these problems.

Key Words: Pulmonary hypertension • Chronic heart failure • Right ventricular function • Prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.